DE69334337D1 - Verfahren zur Identifizierung von Hemmstoffverbindungen der Freisetzung von Beta-Amyloidpeptid (BAP) - Google Patents
Verfahren zur Identifizierung von Hemmstoffverbindungen der Freisetzung von Beta-Amyloidpeptid (BAP)Info
- Publication number
- DE69334337D1 DE69334337D1 DE69334337T DE69334337T DE69334337D1 DE 69334337 D1 DE69334337 D1 DE 69334337D1 DE 69334337 T DE69334337 T DE 69334337T DE 69334337 T DE69334337 T DE 69334337T DE 69334337 D1 DE69334337 D1 DE 69334337D1
- Authority
- DE
- Germany
- Prior art keywords
- beta
- amyloid peptide
- bap
- release
- inhibitor compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96597292A | 1992-10-26 | 1992-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69334337D1 true DE69334337D1 (de) | 2010-08-26 |
Family
ID=25510753
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69334337T Expired - Lifetime DE69334337D1 (de) | 1992-10-26 | 1993-09-01 | Verfahren zur Identifizierung von Hemmstoffverbindungen der Freisetzung von Beta-Amyloidpeptid (BAP) |
DE69333144T Revoked DE69333144T2 (de) | 1992-10-26 | 1993-09-01 | Verfahren zur Identifizierung von Hemmstoffe der Produktion des beta-Amyloidpeptids |
DE0667959T Pending DE667959T1 (de) | 1992-10-26 | 1993-09-01 | VERFAHREN UND ZUSAMMENSETZUNGEN FÜR DEN NACHWEIS VON LÖSLICHEM-g(b)-AMYLOIDPEPTID. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69333144T Revoked DE69333144T2 (de) | 1992-10-26 | 1993-09-01 | Verfahren zur Identifizierung von Hemmstoffe der Produktion des beta-Amyloidpeptids |
DE0667959T Pending DE667959T1 (de) | 1992-10-26 | 1993-09-01 | VERFAHREN UND ZUSAMMENSETZUNGEN FÜR DEN NACHWEIS VON LÖSLICHEM-g(b)-AMYLOIDPEPTID. |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP1298436B1 (de) |
JP (2) | JP3553592B2 (de) |
AT (2) | ATE247282T1 (de) |
CA (1) | CA2105903C (de) |
DE (3) | DE69334337D1 (de) |
DK (2) | DK1298436T3 (de) |
ES (2) | ES2346852T3 (de) |
PT (2) | PT667959E (de) |
WO (1) | WO1994010569A1 (de) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE243746T1 (de) * | 1992-01-07 | 2003-07-15 | Elan Pharm Inc | Transgene tiermodelle fur alzheimer-krankheit |
US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
PT730643E (pt) | 1993-10-27 | 2001-06-29 | Lilly Co Eli | Animais transgenicos portadores do alelo de app com mutacao sueca |
US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
US5484940A (en) * | 1994-11-28 | 1996-01-16 | Grant; Francine S. | Substituted 3-indolyl-5-pyrazolone compounds |
US5986054A (en) * | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
US5849711A (en) * | 1995-06-06 | 1998-12-15 | Athena Neurosciences, Inc. | Cathepsin and methods and compositions for inhibition thereof |
US5783434A (en) * | 1995-06-06 | 1998-07-21 | Tung; Jay S. | Cathepsin and methods and compositions for inhibition thereof |
US6717031B2 (en) | 1995-06-07 | 2004-04-06 | Kate Dora Games | Method for selecting a transgenic mouse model of alzheimer's disease |
EP0876483A1 (de) * | 1996-01-26 | 1998-11-11 | HSC Research and Development Limited Partnership | Nukleinsäuren und proteine im zusammenhang mit der alzheimer krankheit und deren verwendungen |
DE19641180A1 (de) * | 1996-09-24 | 1998-03-26 | Schering Ag | Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung |
US6096782A (en) | 1996-11-22 | 2000-08-01 | Athena Neurosciences, Inc. | N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6642261B2 (en) | 1997-11-21 | 2003-11-04 | Athena Neurosciences, Inc. | N-(aryl/heteroarylacety) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6117901A (en) | 1996-11-22 | 2000-09-12 | Athena Neurosciences, Inc. | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use |
US6683075B1 (en) | 1996-12-23 | 2004-01-27 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use |
US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6218506B1 (en) * | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
JP2003521438A (ja) * | 1997-12-22 | 2003-07-15 | エラン ファーマシューティカルズ,インコーポレイテッド | 多環式α−アミノ−ε−カプロラクタムおよび関連化合物 |
US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6528505B1 (en) | 1998-06-22 | 2003-03-04 | Elan Pharmaceuticals, Inc. | Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6569851B1 (en) | 1998-06-22 | 2003-05-27 | Elan Pharmaceutials, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6774125B2 (en) | 1998-06-22 | 2004-08-10 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6958330B1 (en) | 1998-06-22 | 2005-10-25 | Elan Pharmaceuticals, Inc. | Polycyclic α-amino-ε-caprolactams and related compounds |
US6552013B1 (en) | 1998-06-22 | 2003-04-22 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
CA2361013A1 (en) * | 1999-01-25 | 2000-07-27 | Minerva Biotechnologies Corporation | Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases |
UA81216C2 (en) * | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
BRPI0108676B8 (pt) * | 2000-02-24 | 2021-05-25 | Lilly Co Eli | anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
EP1424892A4 (de) | 2001-08-10 | 2006-08-23 | Univ South Florida | Modulation der angiogenese durch a-beta-peptide |
ATE381346T1 (de) * | 2001-08-17 | 2008-01-15 | Univ Washington | Assayverfahren für alzheimer-krankheit |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
CA2528496C (en) | 2003-06-05 | 2011-04-12 | Elan Pharmaceuticals, Inc. | Acylated amino acid amidyl pyrazoles and related compounds |
WO2005095958A1 (ja) | 2004-03-31 | 2005-10-13 | Angesmg, Inc. | 薬剤候補を同定するためのアッセイ法 |
US20080220445A1 (en) | 2004-10-01 | 2008-09-11 | Takeda Pharmaceutical Company Limited | Method of Screening Transmembrane Enzyme Inhibitory Substance |
EP1820019A4 (de) * | 2004-11-12 | 2008-05-14 | Pfizer | Verfahren zur messung von amyloid-beta-peptiden |
WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
AU2006315686A1 (en) | 2005-11-10 | 2007-05-24 | Roskamp Research, Llc | Modulation of angiogenesis by A-beta peptide fragments |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
WO2011014648A2 (en) * | 2009-07-31 | 2011-02-03 | The General Hospital Corporation | METHODS AND SYSTEM FOR DETECTING SOLUBLE AMYLOID-β |
US20140302532A1 (en) | 2011-04-12 | 2014-10-09 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
CN102955014B (zh) * | 2012-10-19 | 2014-12-31 | 上海吉尔多肽有限公司 | 一种Aβ-淀粉样多肽1-42纯度的检测方法 |
CN105153273A (zh) * | 2015-08-25 | 2015-12-16 | 苏州强耀生物科技有限公司 | 一种制备β-淀粉样多肽1-40纯品的方法 |
US10852309B2 (en) * | 2015-08-25 | 2020-12-01 | Prothena Biosciences Limited | Methods for detecting phosphorylated alpha-synuclein |
CN109696550B (zh) * | 2017-10-20 | 2022-08-26 | 成都蓝瑙生物技术有限公司 | 用于脑中风的发光elisa体液样品稳定化用水溶液 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5262332A (en) * | 1989-04-05 | 1993-11-16 | Brigham And Women's Hospital | Diagnostic method for Alzheimer's disease: examination of non-neural tissue |
US5234814A (en) * | 1989-06-01 | 1993-08-10 | Du Pont Merck Pharmaceutical Company | Diagnostic assay for alzheimer's disease |
US5221607A (en) * | 1989-09-18 | 1993-06-22 | Scios Nova Inc. | Assays and reagents for amyloid deposition |
AU646877B2 (en) * | 1990-06-15 | 1994-03-10 | Scios Nova Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
AU8215391A (en) * | 1990-06-29 | 1992-01-23 | Case Western Reserve University | Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor |
BE1003316A5 (fr) * | 1990-11-27 | 1992-02-25 | Will L F & Cie Sa | Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation. |
US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
-
1993
- 1993-09-01 EP EP02079139A patent/EP1298436B1/de not_active Expired - Lifetime
- 1993-09-01 AT AT93921300T patent/ATE247282T1/de not_active IP Right Cessation
- 1993-09-01 DE DE69334337T patent/DE69334337D1/de not_active Expired - Lifetime
- 1993-09-01 DE DE69333144T patent/DE69333144T2/de not_active Revoked
- 1993-09-01 ES ES02079139T patent/ES2346852T3/es not_active Expired - Lifetime
- 1993-09-01 DK DK02079139.8T patent/DK1298436T3/da active
- 1993-09-01 DE DE0667959T patent/DE667959T1/de active Pending
- 1993-09-01 ES ES93921300T patent/ES2203620T3/es not_active Expired - Lifetime
- 1993-09-01 DK DK93921300T patent/DK0667959T3/da active
- 1993-09-01 JP JP51104194A patent/JP3553592B2/ja not_active Expired - Lifetime
- 1993-09-01 PT PT93921300T patent/PT667959E/pt unknown
- 1993-09-01 WO PCT/US1993/008264 patent/WO1994010569A1/en active IP Right Grant
- 1993-09-01 PT PT02079139T patent/PT1298436E/pt unknown
- 1993-09-01 AT AT02079139T patent/ATE474224T1/de active
- 1993-09-01 EP EP93921300A patent/EP0667959B1/de not_active Revoked
- 1993-09-10 CA CA2105903A patent/CA2105903C/en not_active Expired - Lifetime
-
2003
- 2003-10-02 JP JP2003344850A patent/JP3694303B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU687747B2 (en) | 1998-03-05 |
EP1298436A3 (de) | 2003-07-09 |
DE667959T1 (de) | 2000-04-20 |
EP0667959B1 (de) | 2003-08-13 |
JP2004121251A (ja) | 2004-04-22 |
ATE474224T1 (de) | 2010-07-15 |
JP3553592B2 (ja) | 2004-08-11 |
PT667959E (pt) | 2003-12-31 |
DE69333144T2 (de) | 2004-05-19 |
EP1298436B1 (de) | 2010-07-14 |
CA2105903C (en) | 2011-11-01 |
EP1298436A2 (de) | 2003-04-02 |
AU4844493A (en) | 1994-05-24 |
ES2346852T3 (es) | 2010-10-21 |
WO1994010569A1 (en) | 1994-05-11 |
JPH08502587A (ja) | 1996-03-19 |
DK0667959T3 (da) | 2003-12-08 |
ES2203620T3 (es) | 2004-04-16 |
JP3694303B2 (ja) | 2005-09-14 |
EP0667959A1 (de) | 1995-08-23 |
DE69333144D1 (de) | 2003-09-18 |
PT1298436E (pt) | 2010-10-21 |
EP0667959A4 (de) | 1998-07-08 |
ATE247282T1 (de) | 2003-08-15 |
DK1298436T3 (da) | 2010-10-25 |
CA2105903A1 (en) | 1994-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69334337D1 (de) | Verfahren zur Identifizierung von Hemmstoffverbindungen der Freisetzung von Beta-Amyloidpeptid (BAP) | |
Dowdle, EB, Mustard, P. & Eales | d-Aminolaevulinic acid synthetase activity in normal and porphyric human livers | |
DE69637553D1 (de) | Vorrichtung zum Detektieren eines Analyten und zur Verabreichung einer therapeutischen Substanz | |
AU2392692A (en) | Method and kit for measuring endogenous cytokines | |
Ozaki | Localization and multiple forms of acetylcholinesterase in sea urchin embryos | |
FI923028A (fi) | Foerfarande foer detektering av ben- och andra bindvaevsskador i maenniskor och djur. | |
Jeste et al. | A biochemical study of tardive dyskinesia in young male patients | |
Groothuis et al. | Brain tumors and the blood—brain barrier | |
FR2666096B1 (fr) | Nouveau procede de dosage d'acide desoxyribonucleique present en position extracellulaire dans un milieu. | |
Jepson et al. | Decreased in vivo and in vitro erythropoiesis induced by plasma of ten patients with thymoma, lymphosarcoma, or idiopathic erythroblastopenia | |
DE60037676D1 (de) | Verfahren zur diagnose von rickettsia pulicis | |
ATE117090T1 (de) | Verfahren zur diagnose von tumoren. | |
EP0308926A2 (de) | Methode zur Bestimmung des Verhaltens von Medikamenten in Lebewesen | |
Porter et al. | Correlation of fluorescent antibody, histopathology, and culture on tissues from 372 animals examined for histoplasmosis and blastomycosis | |
Zinner et al. | Cytotoxic effect of dental local anesthetics on tissue culture | |
Schwartz et al. | Quantitative differentiation of minute amounts of the coproporphyrin isomers (I and III) based on fluorescence behavior | |
Arbuthnott et al. | Identification of grafted neurons with fluorescent-labelled microbeads | |
Wogan et al. | Biological monitoring of environmental toxic chemicals. | |
Kagen et al. | Embryonic synthesis of myoglobin in vivo estimated by radioimmunoassay | |
DE19602764C1 (de) | Verfahren zur Bestimmung von Bromelain-Gehalten im Blutplasma | |
RU2136152C1 (ru) | Способ определения естественной резистентности организма птиц | |
TOMOKUNI et al. | The effect of exposing men and animals to lead on the pH activity curves of hepatic and erythrocyte δ-aminolaevulinate dehydratase | |
BABRAHAM | PROCEEDINGS OF THE PHYSIOLOGICAL SOCIETY | |
BROCKEMEYER | A measurement of the efficiency of ointment bases in releasing a local anesthetic by using a pain threshold method | |
Aliu | ABSORPTION, DISTRIBUTION, AND EXCRETION OF IMIDOCARB DIPROPIONATE (3, 3'-BIS-(2-IMIDAZOLIN-2-YL) CARBANILIDE) IN SHEEP. |